Both in Pharmaceuticals
Ocular Therapeutix vs Nuvation Bio
Over the past year OCUL returned −36.8% and NUVB returned −14.5%; their daily moves had a correlation of 0.22.
OCUL −36.8% NUVB −14.5%Growth of $1, one year, split-adjusted
| Metric | OCUL | NUVB |
|---|---|---|
| Price | $7.29 | $4.59 |
| Market cap | $1.60B | $1.61B |
| Today | +8.48% | +0.88% |
| 1 month | −7.4% | −18.3% |
| 6 months | −20.8% | +5.8% |
| Year to date | −40.0% | −48.8% |
| 1 year | −36.9% | −8.9% |
| Revenue growth (YoY) | +0.1% | +555.6% |
| Gross margin | 85.1% | 73.0% |
| Net margin | −584.5% | −198.3% |
| P/E (TTM) | — | — |
| Price / sales | 30.8× | 9.5× |
| Net cash | $525.8M | $399.4M |
| Dividend yield | — | — |
| Volatility (60d) | 75.9% | 53.0% |
| Short % of float | 15.1% | 23.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).